Topiramate Capsule, Extended Release
Product Images NDC 27241-230

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 27241-230). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg (Topiramate 100mg)

Label for Topiramate Extended-Release Capsules 100 mg, containing 30 capsules in a child-resistant package. The label instructs swallowing the capsule whole and intact, cautions not to open, crush, chew, or sprinkle contents on food. Marketed by Ajanta Pharma USA Inc., made in India. Storage conditions and pharmacist dispensing instructions are also noted.*

FDA Label Image

200mg (Topiramate 200mg)

Label for Topiramate Extended-Release Capsules 200 mg by Ajanta Pharma USA Inc. The label notes this bottle contains 30 capsules for oral use. Instructions indicate to swallow capsules whole once daily. Storage instructions mention protecting from moisture and light, with temperature guidelines. The label includes a barcode, NDC 27241-230-30, and safety information stating the packaging is child-resistant and medication should be kept out of reach of children.*

FDA Label Image

25mg (Topiramate 25mg)

Label for Topiramate Extended-Release Capsules, 25 mg, supplied in a package containing 30 capsules. The label states the product is marketed by Ajanta Pharma USA Inc., made in India, child-resistant, and includes storage instructions. It directs pharmacists to dispense a medication guide with each package.*

FDA Label Image

50mg (Topiramate 50mg)

Label for Topiramate extended-release capsules 50 mg, containing 30 capsules per bottle. The label includes dosing instructions to swallow whole without crushing or chewing, storage conditions at 20°-25°C with permitted excursions, and a child-resistant package warning. Marketed by Ajanta Pharma USA Inc., Bridgewater, NJ, and made in India.*

FDA Label Image

Figure1 (Topiramate Figure1)

A Kaplan-Meier curve showing cumulative rates for time to first seizure over 500 days comparing Topiramate 50 mg/day and 400 mg/day doses. The graph plots time in days on the x-axis against cumulative seizure rates on the y-axis, illustrating seizure occurrences in two dosage groups (N=234 for 50 mg/day, N=236 for 400 mg/day) with a statistical p-value of 0.0002.*

FDA Label Image

Figure2 (Topiramate Figure2)

A bar chart showing the change from baseline to double-blind phase in average monthly migraine period rate (+/- standard error) across placebo and three topiramate dosage groups (50 mg/day, 100 mg/day, 200 mg/day) for two separate studies. Bars compare placebo with increasing doses of topiramate, with statistical significance indicated by asterisks for topiramate at 100 mg/day and 200 mg/day doses in both studies.*

FDA Label Image

Structure (Topiramate Structure)

Chemical structure diagram of topiramate, showing its unique arrangement of atoms and bonds, consistent with the active ingredient topiramate used in oral extended-release capsules by Ajanta Pharma USA Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.